Eli Lilly's stock crashed over 14% despite strong Q2 earnings, as disappointing weight-loss pill trial results overshadowed 38% revenue growth and raised guidance.

In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight ...

In the first Phase 3 trial of its once-daily oral GLP-1 pill in people with obesity, drugmaker Eli Lilly said Thursday that ...

Eli Lilly (NYSE: LLY) posted a 38% jump in revenue to $15.6 billion in the second quarter of 2025, driven by surging demand ...

By taking 36 mg once per day - without food and water restrictions - participants lost an average of 12.4 percent of their body weight - about 27.3 pounds (12.4 kilograms). This was over the span of ...

Several studies have found patients taking GLP-1 medications like Wegovy and Mounjaro regain weight, sparking fresh health advice from experts.

Lilly's stock was tumbling as disappointing trial data for an oral weight-loss pill offset an upbeat earnings report and outlook. A previous report had an incorrect company name.

In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight ...

Vizient released its Summer 2025 Spend Management Outlook forecasting a 3.35% increase in pharmaceutical prices in 2026 with healthcare providers seeing increased usage in GLP-1 therapies, specialty ...

Live Updates Live Coverage Updates appear automatically as they are published. Discovery-ing Some Profits 9:40 am Continuing ...

Eli Lilly’s weight loss pill doesn’t appear to work as well as Wall Street had hoped—and it’s forcing investors to yet again rethink the future of the obesity drug market. Lilly shares were down 13.5% ...

Results from a late-stage trial of Eli Lilly's experimental weight-loss pill were disappointing, sending shares of the drugmaker tumbling.